Gastrointestinal Cancer | Specialty

Lower-Dose Chemotherapy Regimen Benefits Elderly, Frail Patients with Gastroesophageal Cancer

May 16th 2019

A lower dose of oxaliplatin and capecitabine had comparable efficacy and minimized adverse events in elderly and frail patients with advanced gastroesophageal cancer.

Dr. Musher on Investigational Combination Therapies in HCC

May 16th 2019

Benjamin Leon Musher, MD, associate professor of medicine, hematology and oncology, at Baylor College of Medicine, discusses emerging combination therapies in hepatocellular carcinoma (HCC).

Dr. Mizrahi on the Importance of Early Genomic Testing in CRC

May 15th 2019

Jonathan Mizrahi, MD, a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center, discusses the importance of early genomic testing in patients with colorectal cancer.

Leveraging Locoregional Therapy and Resection in Metastatic CRC

May 15th 2019

Bassel El-Rayes, MD, further discusses the role of locoregional approaches in borderline and unresectable patients with metastatic colorectal cancer.

TLR Agonists Emerge as Potential New Partner for Checkpoint Inhibitors

May 15th 2019

Toll-like receptors, a group of proteins that are components of innate immunity, are emerging as promising targets in a new wave of immunotherapies under development.

Molecular Advances in Colorectal Cancer Are "Only the Tip of the Iceberg"

May 14th 2019

There has been a significant evolution in the care of patients with metastatic colorectal cancer over the past 20 years. However, this is only the tip of the iceberg and we are going to see more and more subgroups being defined and refined with many more rationally targeted agents matching these alterations.

Dr. Kopetz on the Significance of Tumor Sidedness in CRC

May 13th 2019

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the significance of tumor sidedness in colorectal cancer.

The Future of HCC Management

May 13th 2019

The TARE IO and TACE IO Combination Therapies

May 13th 2019

The CheckMate 9DX and EMERALD 1 and 2 Trials

May 13th 2019

Systemic Plus Locoregional Combination Therapy in HCC

May 13th 2019

FDA Approves Second-Line Ramucirumab in AFP-Elevated HCC

May 11th 2019

The FDA has approved ramucirumab (Cyramza) monotherapy for patients with hepatocellular carcinoma who have an alpha fetoprotein of ≥400 ng/ML and have been previously treated with sorafenib.

Bounty of New HCC Therapies Spurs Need for More Research

May 10th 2019

The optimal integration of new drugs into the treatment paradigm of HCC requires several key developments, including greater research into biomarkers that would help inform therapy choices, earlier treatment for patients diagnosed with HCC, and clinical trials that test combination strategies.

Dr. Shields Discusses the Prevalence of Genetic Testing in CRC

May 9th 2019

Anthony Shields, MD, PhD, professor, Department of Oncology, Molecular Imaging and Diagnostics Program, Karmanos Cancer Institute, discusses the prevalence of genetic testing colorectal cancer.

Dr. Philip on FOLFIRINOX in Locally Advanced Pancreatic Cancer

May 9th 2019

Philip A. Philip, MD, PhD, FRCP, professor, Department of Oncology, Karmanos Cancer Institute, discusses the use of FOLFIRINOX in patients with locally advanced pancreatic cancer.

Vaccine Shows Signs of Stimulatory Effects in Early-Stage CRC

May 8th 2019

A vaccine targeting GUCY2C, a commonly overexpressed protein in patients with early-stage colorectal cancer, induced antibody and T-cell responses toward the specified target and demonstrated an acceptable safety profile in this patient population

Navigating the Complexities of Tumor Sidedness in Colorectal Cancer

May 7th 2019

Scott Kopetz, MD, PhD, FACP, explains the biologic difference between left- and right-sided colorectal cancer and highlights recent research on tumor sidedness and its impact on clinical practice.

Systemic Treatments for NETs: Whom to Treat and How to Sequence

May 2nd 2019

During a recent panel discussion, neuroendocrine tumor experts Simron Singh, MD, MPH, and Jonathan R. Strosberg, MD, provided insight on which patients are the best candidates for these approved treatments and how to sequence therapy to optimize outcomes.

Dr. Anthony on Sequencing Strategies for Patients With NETs

May 2nd 2019

Lowell B. Anthony, MD, FACP, chief, Division of Medical Oncology, University of Kentucky Markey Cancer Center, discusses sequencing strategies for patients with gastroenteropancreatic neuroendocrine tumors.

Dr. Mahipal on Molecular Markers in mCRC

May 2nd 2019

Amit Mahipal, MBBS, senior associate consultant, Division of Medical Oncology, Department of Oncology, associate professor of oncology, Mayo Clinic, discusses emerging molecular markers in patients with metastatic colorectal cancer (mCRC).